Blueprint Genetics was founded five years ago as a Stanford University spin-off company. The aim from the beginning has been to bring genetic diagnostics into the daily routines of healthcare organizations. In this podcast Blueprint Genetics’ co-founder Tero-Pekka Alastalo, MD, Ph.D and Lauren Moissiy, MS, LGC, will discuss the origin of the company and what makes Blueprint Genetic a successful genetic testing provider.
- What differentiates Blueprint Genetics form other genetic testing providers
- What does our unique technology solutions offer
- How transparency in genetic testing benefits the patient care
- What is the future of genetic testing in clinical diagnostics
Tero-Pekka is the chief medical officer, president, and a co-founder of Blueprint Genetics. He is based in San Francisco and in charge of North American operations. He designs diagnostic panels and mutation databases and works with clinical evaluation of genetic data. Tero-Pekka has an MD-PhD degree and is specialized in pediatrics and pediatric cardiology. He has a PhD in molecular and cellular biology as well. In 2007, he continued his research at Stanford University, School of Medicine. During his 3-year postdoctoral training at Stanford University School of Medicine, he focused on the molecular genetic mechanisms of cardiovascular diseases. He continued his cardiovascular research at the University of Helsinki as a principal investigator and the head of an academic research group.
Lauren Moissiy is a trained genetic counselor from San Francisco, CA and is currently the regional sales director for the US with Blueprint Genetics. She has an MS degree in Genetic Counseling from California State University, Stanislaus. Her current focuses are in ophthalmic genetics and genetic causes of sudden unexpected death in the young.